StonvexLoading…
StonvexStonvexStonvexCore line items from CHYM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-05 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $652.73M | $647.39M | $2.19B | $1.59B | $1.05B |
Operating Income | Not available | $46.16M | $-1.04B | $-986.21M | $-921.50M |
Net Income | Not available | $53.46M | $-1.01B | $-965.16M | $-923.38M |
EPS (Diluted) | $-0.01 | $0.13 | $-4.27 | $-5.10 | $-9.44 |
Total Assets | Not available | $1.95B | $1.96B | $1.96B | $1.90B |
Total Liabilities | Not available | $508.94M | $562.90M | $519.04M | $474.38M |
Cash & Equivalents | Not available | $607.68M | $466.25M | $445.03M | $868.28M |
Free Cash Flow OCF − CapEx | Not available | $80.86M | $32.89M | $14.54M | $-888.00K |
Shares Outstanding | Not available | 400.48M | 0 | 0 | 0 |